With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.
Public Company Accounting Oversight Board officials are sounding a cautious note about the spread of artificial intelligence and private equity at audit firms.
Pilot’s Local Partner Program provides software and automation capabilities, as well as advisory services and sales enablement tools, to independent bookkeepers and accounting firms.